46 related articles for article (PubMed ID: 3294038)
1. Reduction in days of illness after long-term treatment with N-acetylcysteine controlled-release tablets in patients with chronic bronchitis.
Rasmussen JB; Glennow C
Eur Respir J; 1988 Apr; 1(4):351-5. PubMed ID: 3294038
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of N-Acetylcysteine for Chronic Obstructive Pulmonary Disease and Chronic Bronchitis.
Zhang L; Xiong Y; Du L
Biomed Res Int; 2022; 2022():9133777. PubMed ID: 35795313
[TBL] [Abstract][Full Text] [Related]
3. The effects of N-acetylcysteine on hepatic, hematologic, and renal parameters in cirrhotic patients: a randomized controlled trial.
Hatami B; Abdi S; Pourhoseingholi MA; Eghlimi H; Rabbani AH; Masoumi M; Hajimohammadebrahim-Ketabforoush M
Gastroenterol Hepatol Bed Bench; 2023; 16(4):432-440. PubMed ID: 38313355
[TBL] [Abstract][Full Text] [Related]
4. Retracted: Efficacy and Safety of N-Acetylcysteine for Chronic Obstructive Pulmonary Disease and Chronic Bronchitis.
International BR
Biomed Res Int; 2023; 2023():9816263. PubMed ID: 38075328
[TBL] [Abstract][Full Text] [Related]
5. Oral acetylcysteine reduces exacerbation rate in chronic bronchitis: report of a trial organized by the Swedish Society for Pulmonary Diseases.
Boman G; Bäcker U; Larsson S; Melander B; Wåhlander L
Eur J Respir Dis; 1983 Aug; 64(6):405-15. PubMed ID: 6350033
[TBL] [Abstract][Full Text] [Related]
6. Orally administered N-acetylcysteine may improve general well-being in patients with mild chronic bronchitis.
Hansen NC; Skriver A; Brorsen-Riis L; Balsløv S; Evald T; Maltbaek N; Gunnersen G; Garsdal P; Sander P; Pedersen JZ
Respir Med; 1994 Aug; 88(7):531-5. PubMed ID: 7972979
[TBL] [Abstract][Full Text] [Related]
7. [Multicenter, double-blind study of oral acetylcysteine vs. placebo].
Brocard H; Charpin J; Germouty J
Eur J Respir Dis Suppl; 1980; 111():65-9. PubMed ID: 7011834
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability of oral acetylcysteine (Fabrol) in chronic bronchitis: a double-blind placebo controlled study.
Jackson IM; Barnes J; Cooksey P
J Int Med Res; 1984; 12(3):198-206. PubMed ID: 6376210
[TBL] [Abstract][Full Text] [Related]
9. A controlled trial of intermittent oral acetylcysteine in the long-term treatment of chronic bronchitis.
Grassi C; Morandini GC
Eur J Clin Pharmacol; 1976 Mar; 09(5-6):393-6. PubMed ID: 786665
[TBL] [Abstract][Full Text] [Related]
10. Long-term oral acetylcysteine in chronic bronchitis. a double-blind controlled study.
Eur J Respir Dis Suppl; 1980; 111():93-108. PubMed ID: 7011836
[No Abstract] [Full Text] [Related]
11. Irish general practice study of acetylcysteine (Fabrol) in chronic bronchitis.
Tattersall AB; Bridgman KM; Huitson A
J Int Med Res; 1984; 12(2):96-101. PubMed ID: 6373444
[TBL] [Abstract][Full Text] [Related]
12. Effect of oral N-acetylcysteine on mucus clearance.
Millar AB; Pavia D; Agnew JE; Lopez-Vidriero MT; Lauque D; Clarke SW
Br J Dis Chest; 1985 Jul; 79(3):262-6. PubMed ID: 3893512
[TBL] [Abstract][Full Text] [Related]
13. A double-blind parallel study of acetylcysteine-isoproterenol and saline-isoproterenol in patients with chronic obstructive lung disease.
Cato A; Goldstein I; Millman M
J Int Med Res; 1977; 5(3):175-83. PubMed ID: 330289
[TBL] [Abstract][Full Text] [Related]
14. Bottom-up analysis of emergent properties of N-acetylcysteine as an adjuvant therapy for COVID-19.
Dominari A; Hathaway Iii D; Kapasi A; Paul T; Makkar SS; Castaneda V; Gara S; Singh BM; Agadi K; Butt M; Retnakumar V; Chittajallu S; Taugir R; Sana MK; Kc M; Razzack S; Moallem N; Alvarez A; Talalaev M
World J Virol; 2021 Mar; 10(2):34-52. PubMed ID: 33816149
[TBL] [Abstract][Full Text] [Related]
15. Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease.
Poole P; Sathananthan K; Fortescue R
Cochrane Database Syst Rev; 2019 May; 5(5):CD001287. PubMed ID: 31107966
[TBL] [Abstract][Full Text] [Related]
16. N-acetylcysteine in COPD: why, how, and when?
Sanguinetti CM
Multidiscip Respir Med; 2015; 11():8. PubMed ID: 26855777
[TBL] [Abstract][Full Text] [Related]
17. Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis.
Cazzola M; Calzetta L; Page C; Jardim J; Chuchalin AG; Rogliani P; Matera MG
Eur Respir Rev; 2015 Sep; 24(137):451-61. PubMed ID: 26324807
[TBL] [Abstract][Full Text] [Related]
18. Prevention of acute exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline.
Criner GJ; Bourbeau J; Diekemper RL; Ouellette DR; Goodridge D; Hernandez P; Curren K; Balter MS; Bhutani M; Camp PG; Celli BR; Dechman G; Dransfield MT; Fiel SB; Foreman MG; Hanania NA; Ireland BK; Marchetti N; Marciniuk DD; Mularski RA; Ornelas J; Road JD; Stickland MK
Chest; 2015 Apr; 147(4):894-942. PubMed ID: 25321320
[TBL] [Abstract][Full Text] [Related]
19. Update on the pathological processes, molecular biology, and clinical utility of N-acetylcysteine in chronic obstructive pulmonary disease.
Tse HN; Tseng CZ
Int J Chron Obstruct Pulmon Dis; 2014; 9():825-36. PubMed ID: 25125976
[TBL] [Abstract][Full Text] [Related]
20. Long-time treatment by low-dose N-acetyl-L-cysteine enhances proinflammatory cytokine expressions in LPS-stimulated macrophages.
Ohnishi T; Bandow K; Kakimoto K; Kusuyama J; Matsuguchi T
PLoS One; 2014; 9(2):e87229. PubMed ID: 24504121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
